Tumors with this variant are responsive to treatment with BRAF inhibitors (e.g., dabrafenib, vemurafenib) and in combination with MEK inhibitors this has been shown to be an effective treatment strategy for melanoma [57]. The gene discussed is MAP2K7; the disease is melanoma.